Ovarian Cancer Coverage from Every Angle

FDA Accepts sNDA for Niraparib in First-Line Maintenance Treatment of Ovarian Cancer

By: Jocelyn Solis-Moreira, MS
Posted: Monday, March 2, 2020

On February 24, the U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application (sNDA) for the PARP inhibitor niraparib as a first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of BRCA mutation status. It is currently approved in the United States as a maintenance treatment for women with advanced ovarian cancer following three or more chemotherapy regimens.

The application is supported by data from the phase III PRIMA clinical trial (ENGOT-OV26/GOG-3012) presented simultaneously at the 2019 European Society for Medical Oncology Congress and published in The New England Journal of Medicine. This double-blind study assessed the efficacy of niraparib as first-line maintenance therapy in 733 women with newly diagnosed advanced (stage III or IV) ovarian cancer after a response to first-line platinum-based chemotherapy. Half of the patients had tumors with homologous-recombination deficiency.

The study met its primary endpoint: patients who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the absence or presence of homologous-recominbation deficiency. At a 24-month interim analysis, the rate of overall survival favored niraparib as well (84% vs. 77%). The most common adverse events of grade 3 or higher were anemia (31%), thrombocytopenia (28.7%), and neutropenia (12.8%). No treatment-related deaths were reported.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.